canada semaglutide patent As patents on weight-loss drugs expire, doctors and patients hotly anticipate cheaper generics Ozempic's patent problem: how Novo

Those with pre-existing mental health conditions may require closer monitoring and coordinated care between GP, diabetes specialists, and mental health professionals

S., & Choi, K

Long-term concerns include the loss of muscle mass, the likelihood of weight regain after stopping therapy, and potential risks such as arthritis and pancreatitis

consumers are responding to financial pressures in the food and beverage space and what it means for your business strategy

Push the air from the syringe into the vial

The distinction that matters is whether GLP-1 receptor agonists cause a disproportionate loss of muscle relative to fat